Ekso Bionics Holdings (EKSO) Stock Overview
Designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Europe, the Middle East, Africa, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
EKSO Community Fair Values
See what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Ekso Bionics Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.31 |
| 52 Week High | US$14.97 |
| 52 Week Low | US$2.73 |
| Beta | 0.82 |
| 1 Month Change | 25.83% |
| 3 Month Change | 13.22% |
| 1 Year Change | -41.97% |
| 3 Year Change | -69.49% |
| 5 Year Change | -94.31% |
| Change since IPO | -99.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| EKSO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 12.3% | 0.9% | 2.6% |
| 1Y | -42.0% | 3.4% | 14.2% |
Return vs Industry: EKSO underperformed the US Medical Equipment industry which returned 5% over the past year.
Return vs Market: EKSO underperformed the US Market which returned 14.8% over the past year.
Price Volatility
| EKSO volatility | |
|---|---|
| EKSO Average Weekly Movement | 11.0% |
| Medical Equipment Industry Average Movement | 8.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EKSO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EKSO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 64 | Scott Davis | www.eksobionics.com |
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EVO, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. It also offers EksoCare offering an extended warranty and premium service options, repairs and maintenance services, and training programs.
Ekso Bionics Holdings, Inc. Fundamentals Summary
| EKSO fundamental statistics | |
|---|---|
| Market cap | US$18.02m |
| Earnings (TTM) | -US$10.66m |
| Revenue (TTM) | US$14.75m |
Is EKSO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EKSO income statement (TTM) | |
|---|---|
| Revenue | US$14.75m |
| Cost of Revenue | US$6.86m |
| Gross Profit | US$7.89m |
| Other Expenses | US$18.55m |
| Earnings | -US$10.66m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.14 |
| Gross Margin | 53.48% |
| Net Profit Margin | -72.28% |
| Debt/Equity Ratio | 44.0% |
How did EKSO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/24 12:37 |
| End of Day Share Price | 2025/12/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ekso Bionics Holdings, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Chodaczek | B. Riley Securities, Inc. |
| Dan Scovel | Edison Investment Research |
| Tom Grady | Edison Investment Research |



